Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
Cells · 15.06.2023 · 12 (12) · 1639
DOI: 10.3390/cells12121639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 15.06.2023. Verfasst von Katja Zappe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open Access Publishing Fund of the University of Vienna.
Abstract (Originalsprache)
The repair protein O6-methylguanine-DNA methyltransferase (MGMT) is regulated epigenetically, mainly by the methylation of the MGMT promoter. MGMT promoter methylation status has emerged as a prognostic and predictive biomarker for patients with newly diagnosed glioblastoma (GBM). However, a strong negative correlation between MGMT promoter methylation and MGMT protein expression cannot be applied as a rule for all GBM patients. In order to investigate if the DNA methylation status of MGMT enhancers is associated with MGMT promoter methylation, MGMT expression, and the overall survival (OS) of GBM patients, we established assays based on high-resolution melting analysis and pyrosequencing for one intragenic and three intergenic MGMT enhancers. For CpGs in an enhancer located 560 kb upstream of the MGMT promoter, we found a significant negative correlation between the methylation status and MGMT protein levels of GBM samples expressing MGMT. The methylation status of CpGs in the intragenic enhancer (hs696) was strongly negatively correlated with MGMT promoter methylation and was significantly higher in MGMT-expressing GBM samples than in MGMT-non-expressing GBM samples. Moreover, low methylation of CpGs 01–03 and CpGs 09–13 was associated with the longer OS of the GBM patients. Our findings indicate an association between MGMT enhancer methylation and MGMT promoter methylation, MGMT protein expression, and/or OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
- Department of Neurosurgery, Kepler University Hospital GmbH, Johannes Kepler University, 4040 Linz, Austria.
ORCID-Profile: Katja Zappe, Simon Pflug, Margit Cichna-Markl
Förderung
- Open Access Publishing Fund of the University of Vienna
Zitieren
APA
Zappe, K., Pühringer, K., Pflug, S., Berger, D., Böhm, A., Spiegl-Kreinecker, S., & Cichna-Markl, M. (2023). Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma. Cells, 12(12), 1639. https://doi.org/10.3390/cells12121639
Vancouver
Zappe K, Pühringer K, Pflug S, Berger D, Böhm A, Spiegl-Kreinecker S, et al. Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma. Cells. 2023;12(12):1639. doi:10.3390/cells12121639
BibTeX
@article{Zappe2023,
author = {Zappe, Katja and Pühringer, Katharina and Pflug, Simon and Berger, Daniel and Böhm, Andreas and Spiegl-Kreinecker, Sabine and Cichna-Markl, Margit},
title = {Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma},
journal = {Cells},
year = {2023},
volume = {12},
number = {12},
pages = {1639},
doi = {10.3390/cells12121639}
}
EUVIMED